[Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia]
- PMID: 33349731
- DOI: 10.1708/3503.34896
[Personalized treatment of depression phenotypes: role of trazodone in depression with insomnia]
Abstract
Aim: This paper completes a series of three manuscripts on the clinically relevant evidence of the use of trazodone in major depressive disorder. The first paper provided general clinical guidance on the use of trazodone in major depressive disorder. The second paper evaluated the different clinical scenarios in which trazodone prolonged-release or trazodone Contramid® once-a-day may be more indicated. This third and last paper evaluates the clinically relevant evidence about the use of trazodone in major depressive disorder (MDD) with insomnia.
Methods: Medline and Cochrane Library searches were performed using the keywords 'trazodone' AND 'depression' AND 'insomnia', to identify the most relevant literature on the use of trazodone in patients with MDD and insomnia. European and the United States prescribing information was reviewed as well. More weight was given to the information that was deemed as most relevant for daily clinical practice.
Results: Trazodone is an effective medication for patients with MDD and insomnia.
Discussion: Trazodone is efficacious for the treatment of a broad array of depressive symptoms and is particularly useful for patients presenting with insomnia as one of the symptoms of depression.
Conclusions: Trazodone improves sleep and depression and is particularly helpful for patients whose symptoms of depression include insomnia.
Similar articles
-
[Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].Riv Psichiatr. 2016 Jul-Aug;51(4):123-128. doi: 10.1708/2342.25112. Riv Psichiatr. 2016. PMID: 27727261 Review. Italian.
-
Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.Riv Psichiatr. 2019 Jul-Aug;54(4):137-149. doi: 10.1708/3202.31796. Riv Psichiatr. 2019. PMID: 31379379 Review.
-
[Personalized medicine with extended-release trazodone and/or once-a-day trazodone: from research trials to clinical practice].Riv Psichiatr. 2020 Sep-Oct;55(5):255-261. doi: 10.1708/3457.34457. Riv Psichiatr. 2020. PMID: 33078017 Italian.
-
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.Psychopharmacol Bull. 2009;42(4):5-22. Psychopharmacol Bull. 2009. PMID: 20581790 Clinical Trial.
-
Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.Neuropsychobiology. 2003;48(4):194-208. doi: 10.1159/000074638. Neuropsychobiology. 2003. PMID: 14673218 Clinical Trial.
Cited by
-
Forensic Aspects of a Fatal Intoxication Involving Acetaminophen, Citalopram and Trazodone: A Case Report.Toxics. 2022 Aug 22;10(8):486. doi: 10.3390/toxics10080486. Toxics. 2022. PMID: 36006165 Free PMC article.
-
Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum.Breastfeed Med. 2021 Nov;16(11):922-925. doi: 10.1089/bfm.2021.0191. Epub 2021 Aug 3. Breastfeed Med. 2021. PMID: 34348038 Free PMC article.
-
Advancing Antidepressive Agents: Drug Discovery and Polymer-Based Drug Delivery Systems for Improved Treatment Outcome.Biomedicines. 2025 Apr 29;13(5):1081. doi: 10.3390/biomedicines13051081. Biomedicines. 2025. PMID: 40426909 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical